Next Article in Journal
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
Previous Article in Journal
Frequency and Localization of Second Primary Tumors in Patients with Oropharyngeal Carcinoma—The Influence of the Human Papilloma Virus
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 8
10.3390/cancers13081757
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Systematic Review
Peer-Review Record

Systematic Review of Recurrent Osteosarcoma Systemic Therapy

Cancers 2021, 13(8), 1757; https://doi.org/10.3390/cancers13081757
by Ioanna Gazouli 1,†, Anastasios Kyriazoglou 2,*,†, Ioannis Kotsantis 2, Maria Anastasiou 2, Anastasios Pantazopoulos 2, Maria Prevezanou 2, Ioannis Chatzidakis 2, Georgios Kavourakis 2, Panagiota Economopoulou 2, Vasileios Kontogeorgakos 3, Panayiotis Papagelopoulos 3 and Amanda Psyrri 2
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Cancers 2021, 13(8), 1757; https://doi.org/10.3390/cancers13081757
Submission received: 13 March 2021 / Revised: 28 March 2021 / Accepted: 3 April 2021 / Published: 7 April 2021
(This article belongs to the Section Cancer Therapy)

Round 1

Reviewer 1 Report

The manuscript entitles "Systematic review of recurrent osteosarcoma systemic therapy" by Ioanna  Gazouli et al. is a very interesting and comprehensive overview of the current therapeutic strategies available or under investigation to treat recurrent OS. 
The article is convincing and very well written.  The reviewer has only one comment to this complete review which is how could prersonalized medicine approaches and technologies help the development of secure and effective therapies?

Author Response

Hopefully, in the era of personalized medicine, patients suffering from recurrent osteosarcoma or other infrequent malignancies may aspire to a better future.  Innovative technologies such as Next Generation Sequencing, recognition of cancer and immune molecular signatures, methylation arrays and real time mutational profile assessment by liquid biopsies, promise to lay a foundation for patient-tailored treatments with clinically meaningful results.

Author Response File: Author Response.docx

Reviewer 2 Report

In their manuscript entitled “Systematic review of recurrent osteosarcoma systemic therapy”, Gazouli and colleagues review the recent papers which reported systemic treatment options in recurrent and/or metastatic osteosarcoma.  Osteosarcoma is a malignant tumor that is extremely difficult to treat for recurrence and research for its determination of truly appropriate treatment strategies is very important.  From that point of view, this review is very informative and covers the recent literature widely, the conclusion is adequate.

Author Response

Thank you for considering our paper and for your valuable comments.

Reviewer 3 Report

A comprehensive review of status quo and potential treatments.

OF course would like NEW and innovative treatments to work but this shows just how hard it is to do this.

Author Response

Thank you for your intriguing comment.

The discovery of applicable, novel treatments seems to be, indeed, very demanding-hopefully, future studies will try to satisfy these expectations. 

Back to TopTop